Resistance mutations to different classes of antiretroviral agents predict virological failure in HIV+ patients with low level viremia: a retrospective study from the ARCA cohort- Francesca Lombardi

European Meeting on HIV & Hepatitis 2018

Dynamics of therapy options for HIV-1 infected patients with historical multi-drug resistance (MDR), based on deep-sequencing of proviral DNA – First Results from the LOWER Study- Alexander Thielen

European Meeting on HIV & Hepatitis 2018

Factors associated with virological response and resistance profile in HIV-1 infected patients starting first-line integrase inhibitors based regimen in clinical settings- Maria Santoro

European Meeting on HIV & Hepatitis 2018

Mutations in the 3’-polypurine tract of HIV-1 point to a new integrase strand transfer inhibitor (INSTI) resistance mechanism in vivo- Jeroen van Kampen

European Meeting on HIV & Hepatitis 2018

Novel simplified bioinformatics for NGS data analysis- Marc Noguera-Julian, PhD

European Meeting on HIV & Hepatitis 2018

Management of hepatitis C therapy failures - clinical perspective- Sanjay Bhagani, BSc FRCP

European Meeting on HIV & Hepatitis 2018

Management of hepatitis C therapy failures - virological perspective- Francesca Ceccherini– Silberstein, PhD

European Meeting on HIV & Hepatitis 2018

Selection of fitness-associated substitutions in patients failing NS5A inhibitors based therapy : analysis of HCV full-length genome deep sequencing by means of shotgun metagenomics- Slim Fourati

European Meeting on HIV & Hepatitis 2018

Evaluation of pre-treatment risk factors associated with failure in HCVinfected patients naive to direct acting antivirals: particular focus on natural resistance- Silvia Barbaliscia

European Meeting on HIV & Hepatitis 2018

Acute hepatitis A to E, diagnosis and management - Thomas Berg, MD

European Meeting on HIV & Hepatitis 2018

B/F/TAF in treatment-naïve HIV-1 and HIV-1 RNA suppressed switch patients- Kirsten White, MD, PhD

European Meeting on HIV & Hepatitis 2018

Clinical development of ABX464, drug candidate for HIV functional cure- Jean-Marc Steens, MD

European Meeting on HIV & Hepatitis 2018

Reduced drug regimens- Andrea De Luca, MD

European Meeting on HIV & Hepatitis 2018

What is the place of the monoclonal antibodies in the clinic- Julià Blanco, PhD

European Meeting on HIV & Hepatitis 2018

Hepatitis E in HIV- Kenneth Sherman, MD, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

News on hepatitis delta and HIV infections- Vincent Soriano, MD, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

Management of HCV in intravenous drug users: special considerations- Rui Sarmento e Castro, MD, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

EASL highlights 2017- Jürgen Rockstroh, MD

International Workshop on HIV & Hepatitis Co-infection 2017

Management of end-stage liver disease in HIV patients- Ana Morbey, MD

International Workshop on HIV & Hepatitis Co-infection 2017

New insights in management of HIV/HBV co-infected patients- Juan Berenguer, MD

International Workshop on HIV & Hepatitis Co-infection 2017

HBV cure: what is coming in 5 – 10 years?- Patrick Kennedy, MD

International Workshop on HIV & Hepatitis Co-infection 2017

Debate case based: Do we need resistance testing in HCV therapy to guide decision making? Pro stance- Francesca Ceccherini– Silberstein, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

Special considerations before / during / after DAA therapy- Kosh Agarwal, MD

International Workshop on HIV & Hepatitis Co-infection 2017

Virologist's perspective - Charles Boucher, MD, PhD

International Workshop on HIV & Hepatitis Co-infection 2017